Novo Nordisk invests billions in expanding its production capacity
Av The investment includes a new facility of approximately 65,000 square metres, providing additional production capacity and flexibility and enabling Novo Nordisk to develop its product portfolio in serious chronic diseases.
“This significant investment will ensure the continuous development of our late-stage pipeline into deliveries of key medicines for the treatment of patients worldwide,” said Henrik Wulff, Vice President of Product Supply, Quality and IT, in a press release.
Construction has begun and the facility is expected to start producing active pharmaceutical ingredients in early 2029. When the new manufacturing facility is completed, Novo Nordisk expects 340 new jobs to be generated.
This massive investment coincides with the 100th anniversary of the company’s founding in 1923.
Artikeln är en del av vårt tema om News in English.